Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection

Antiviral Therapy

Volumn 11, Issue 3, 2006, Pages 343-350

  Lazaro, Estibaliz ^a   Coureau, Gaelle ^b   Guedj, Jérémie ^b   Blanco, Patrick ^a,c   Pellegrin, Isabelle ^a   Commences, Daniel ^b   Dabis, François ^b   Moreau, Jean François ^a,c   Pellegrin, Jean Luc ^a   Thiébaut, Rodolphe ^b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c CNRS Bordeaux Segalen University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CLARITHROMYCIN; ETHAMBUTOL; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RIFABUTIN; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LYMPHOCYTE COUNT; MALE; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INFECTION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION;

EID: 33744778114     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
2. Lederman HM, Williams PL, Wu JW, et al. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4(+) cell depletion. J Infect Dis 2003; 188:1794-1803.
3. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
4. Rouzioux C, Hubert JB, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 2005; 192:46-55.
5. D'Amico R, Yang YJ, Mildvan D, et al. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: Analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol 2005; 25:106-115.
6. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999; 13:669-676.
7. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: Evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290-1294.
8. Thiébaut R, Jacqmin-Gadda H, Walker S, et al. Determinants of response to first HAART regimen in naive patients with an estimated time since HIV seroconversion. HIV Med 2006; 7:1-9.
9. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27:251-259.
10. Carrieri MP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther 2003; 8:585-594.
11. Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15:735-746.
12. Sacre K, Carcelain G, Cassoux N, et al. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med 2005; 201:1999-2010.
13. Havlir DV, Schrier RD, Torriani FJ, Chervenak K, Hwang JY, Boom WH. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. J Infect Dis 2000; 182:1658-1663.
14. Zeller V, Truffot C, Agher R, et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002; 34:662-667.
15. Shafran SD, Mashinter LD, Phillips P, et al. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med 2002; 137:734-737.
16. Cassol E, Page T, Mosam A, et al. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. J Infect Dis 2005; 191:324-332.
17. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
18. Antonucci G, Girardi E, Cozzi-Lepri A, et al. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis 2005; 40:e101-e109.
19. Braitstein P, Zala C, Yip B, et al. Immunologic Response to Antiretroviral Therapy in Hepatitis C Virus-Coinfected Adults in a Population-Based HIV/AIDS Treatment Program. J Infect Dis 2006; 193:259-268.
20. Graham C, Koziel M. Why should hepatitis C affect immune reconstitution in HIV-1-infected patients? Lancet 2000; 356:1865-1866.
21. Laskus T, Radkowski M, Jablonska J, et al. Human immunodeficiency virus facilitates infection/replication of hepatitis C virus in native human macrophages. Blood 2004; 103:3854-3859.
22. Maciejewski JP, St Jeor SC. Human cytomegalovirus infection of human hematopoietic progenitor cells. Leuk Lymphoma 1999; 33:1-13.
23. Randolph-Habecker J, Iwata M, Torok-Storb B. Cytomegalovirus mediated myelosuppression. J Clin Virol 2002; 25 Suppl 2:S51-S56.
24. Goldmacher VS. Cell death suppression by cytomegaloviruses. Apoptosis 2005; 10:251-265.
25. Inderlied CB, Kemper CA, Bermudez LE. The Mycobacterium avium complex. Clinical Microbiol Rev 1993; 6:266-310.
26. Aberg JA, Williams PL, Liu T, et al. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. J Infect Dis 2003; 187:1046-1052.
27. MacGregor RR, Hafner R, Wu JW, et al. Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study. AIDS Res Hum Retroviruses 2005; 21:689-695.
28. Thiébaut R, Morlat P, Jacqmin-Gadda H, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. AIDS 2000; 14:971-978.
29. Thiébaut R, Jacqmin-Gadda H, Babiker A, Commenges D. Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+cell count and HIV RNA viral load in response to treatment of HIV infection. Stat Med 2005; 24:65-82.
30. Hafner R, Inderlied CB, Peterson DM, et al. Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis 1999; 180:438-447.
31. Gascon P, Sathe SS, Rameshwar P. Impaired erythropoiesis in the acquired immunodeficiency syndrome with disseminated Mycobacterium avium complex. Am J Med 1993; 94:41-48.
32. Kremer L, Estaquier J, Wolowczuk I, Biet F, Ameisen JC, Locht C. Ineffective cellular immune response associated with T-cell apoptosis in susceptible Mycobacterium bovis BCG-infected mice. Infect Immun 2000; 68:4264-4273.
33. Isgro A, Mezzaroma I, Aiuti A, et al. Decreased apoptosis of bone marrow progenitor cells in HIV-1-infected patients during highly active antiretroviral therapy. AIDS 2004; 18:1335-1337.
34. Benveniste O, Flahault A, Rollot F, et al. Mechanisms involved in the low-level regeneration of CD4(+) cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005; 191:1670-1679.
35. Freund YR, Dousman L, Mohagheghpour N. Prophylactic clarithromycin to treat mycobacterium avium in HIV patients receiving zidovudine may significantly increase mortality by suppressing lymphopoiesis and hematopoiesis. Int Immunopharmacol 2002; 2:1465-1475.
36. Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
37. Bermudez LE, Petrofsky M, Stevens P. Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice. Immunology 1998; 94:297-303.
38. Nielsen SD, Ersboll AK, Mathiesen L, Nielsen JO, Hansen JES. Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected patients. J Infect Dis 1998; 178:1299-1305.
39. Levy Y, Durier C, Krzysiek R, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003; 17:343-351.
40. Estaquier J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC. Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood 1996; 87:4959-4966.
41. Kovacs JA, Lempicki RA, Sidorov IA, et al. Induction of prolonged survival of CD4(+) T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005; 115:2139-2148.